Evaluation and Management of Neonatal Supraventricular Tachycardia

Supraventricular Tachycardia (SVT) is the most frequent arrhythmia requiring a medical treatment in neonates.
The aim of our study was to evaluate and manage neonatal supraventricular tachycardia.
This study was performed on 22 newborns that were diagnosed with SVT at two neonatal intensive care units (NICU) in south west of Iran from October 2012 to October 2015. Data on gender, age, weight, maternal age, gestational age, presence of congenital heart disease, blood pressure in admission, duration of hospitalization period, duration of SVT, medicine for the control of SVT, list of medicine administered at releasing time were collected. Echocardiography was performed for all patients. Data was analyzed by the SPSS version 18 software.
Twelve neonates were male (54.5%) and ten (45.5%) were female. The mean age was 11.68 ± 8.17 days. Three neonates (13.6%) had congenital heart disease. The mean duration of hospitalization was 6.54 ± 3.98 days. Nine patients (41%) only had responded adenosine. One patient had hypotensive that received D/C shock.
We concluded that in most SVT patients, conventional treatment can be helpful and an only minor percentage of patients need to receive flecainide as the last line of treatment.